When it comes to investing in stocks, that is not easy. Sometimes it’s tricky also, as we have to be a pro in researching and predicting a stock price. In this article, we will talk about BBIO stock, its price, company profile, a couple of data and finance, and finally, whether you should invest in the stock or not.
BBIO Stock: Company Profile
Before investing in any stocks, the first thing that you must do is research the company. Because that will you whether the company has potential or not, and the more potential a company has, the more the stock price will rise. So, let’s look into the company’s profile that backs the BBIO stock.
|Company Name||BridgeBio Pharma, Inc.|
|Phone Number||650 391 9740|
|Address||421 Kipling Street Palo Alto, CA, 94301, United States|
What Does BridgeBio Pharma, Inc. Do?
The company mainly engages in making medicine for genetic diseases. The company is responsible for discovering, developing, and delivering medicines. There are currently 30 different development programs, including product candidates and early discovery of development. If we talk about products that the company is developing, then there are BBP-265, AG10, transthyretin, small molecule stabilizer, and TTR.
Right now, the TTR is in its third stage of the clinical trial. The compound is for treating TTR amyloidosis-cardiomyopathy, or you can say ATTR-CM. Then there is BBP-831, which is an FGFR1-3 inhibitor and a small molecule. This medicine is in its second stage. And scientists use this medicine for treating achondroplasia in pediatric patients.
There is also a gene transfer product named AAV5. It is in its second phase of a clinical trial. This medicine is used for congenital adrenal hyperplasia, or you can call this CAH. The medicine can also be used for 21OHD or 21-hydroxylase deficiency. The company is responsible for developing Encaleret. It is a small antagonist of calcium that can be used as a sensing receptor or CaSR.
There are also other medicines for treating hyperoxaluria, kidney stones, oncology mendelian, and gene therapy diseases. The company has a collaboration with Leland Stanford Junior University. They have also been licensed to work with different universities like the Leidos Biomedical Research, Inc. and the Regents of the University of California. The headquarter is in Palo Alto, California, and it started working in 2015.
The revenue was $40 million in 2019. In 2020, the revenue was around $10 million, and then in 2020, there was a rapid increase that it was $70 million. As of December 2022, the revenue is around $80 million. So, the revenue of the company is quite good.
Market Cap- $1.02 Billion
Total Debt- $1.72
Cash- $591.98 Million
Enterprise Value- $2.15 Billion
|Type||Shares Outstanding (%)||Common Stock Held||Market Value|
|Insiders/Individuals||6.10%||$9.48 Million||$64.63 Million|
|Hedge Fund Managers||17.13%||$26.62 Million||$181.56 Million|
|VC/PE Firms||19.99%||$31.06 Million||$211.84 Million|
|Total||100.00%||$155.40 Million||$1.06 Billion|
Frequently Asked Questions: (FAQs):-
Here are a couple of questions and answers that most people ask.
Ans: There are expert analysts who have reviewed the BBIO stock. And according to them, BBIO is very bullish on average. So, for a wall street consensus of buy, this stock is not a good investment.
Ans: You will find BridgeBio Pharma, Inc. on NASDAQ, and the symbol of the stock is BBIO. And if you want to buy a BBIO stock, then one stock will cost you around $6.82.
Ans: If you want to buy BridgeBio Pharma, Inc. stock or BBIO stock, then you will find the stock on NASDAQ.
Ans: The stock symbol of BridgeBio Pharma, Inc. is BBIO, and the current BBIO stock price is approx $6.82. And the stock trends under NASDAQ.
Ans: According to many stock analysts, the BBIO is Bullish. And when it comes to Bearish, it is rated 0, and according to Neutral, the rate is also 0. There is also a Wall Street analysis, and there is no good review at all.
Ans: According to many stock analysts and Wall Street, the issued price target of BBIO is $22.60. This means the company is targeting to increase the value of the stock.
Ans: If we talk about quarterly earnings, then the company earned a total of $-0.93 per share. And the EPS surprise was $0.04. Right now, the latest EPS is $-0.94.
Ans: You will find BBIO stock on the NASDAQ. Yes, you can buy BBIO stock from any online brokerage account in the USA. Some examples of online brokerage accounts are Merrill Edge, Charles Schwab, and E*TRADE. If you are a premium subscriber, then you can easily buy BBIO stock.
Ans: The mailing address is 421 Kipling Street, Palo Alto, CA 94301, United States. Or, you can call on the phone number of BridgeBio Pharma, Inc., which is 650 391 9740.
Ans: BBIO shareholders own other stocks as well. These stocks are VCEL, BLU, IMGO, VRDN, CVAC, etc.
So, should you invest in BBIO stock?
The answer can be both yes and no. On the one hand, the company has the potential to do great in the market. And on the other hand, there have been some recent drops in revenues, and the decrease in the stock price tells a different story. So, this stock is definitely not for making a lot of money with quick succession. Rather, you can invest and wait for a couple of years to get a significant profit.
If you have any more queries, feel free to ask in the comment section below.
Have A Look :-